Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 543-560

  Manetti, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Actin cytoskeletal dynamics; Actin depolymerizing factor; Cancer cells; Cofilin; LIM domain kinases; Metastasis; Small molecule LIMK inhibitors

Indexed keywords

3 AMINOTHIENO[2,3 D]PYRIDINE 2 CARBOXAMIDE DERIVATIVE; ACTIN; ANTINEOPLASTIC AGENT; CFXA PROTEIN; COFILIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DEATH RECEPTOR; DIPHENYLUREA DERIVATIVE; K RAS PROTEIN; LIM KINASE; LIM KINASE 1; LIM KINASE 2; NARCICLASINE; PAXILLIN; PHENYLPYRAZOLYLTHIAZOLE DERIVATIVE; PHENYLPYRIMIDINE DERIVATIVE; PLEXIN C1; POLYPEPTIDE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE[2,3 D]PYRIMIDINE DERIVATIVE; RESVERATROL; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE PROTEINASE; TETRACYCLIC PYRIDOCARBAZOLE; THIENO[2,3 D]PYRIMIDIN 4 AMINE DERIVATIVE; THIENO[3,2 D]PYRIMIDIN 4 AMINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIN FILAMENT; ACTIN POLYMERIZATION; AMINO ACID SEQUENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL MOTILITY; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENOTOXICITY; GLIOBLASTOMA; HEPATOMA CELL; IMMOBILIZED CELL; INTRACELLULAR SIGNALING; MELANOMA CELL; METASTASIS; NEUROBLASTOMA; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TUMOR CELL; UBIQUITINATION; ULTRAVIOLET B RADIATION; UTERINE CERVIX CARCINOMA;

EID: 84861725358     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673266     Document Type: Article

References (102)

1. HUGO Gene Nomenclature Committee. http://www.genenames. org/data/hgnc_data.php?hgnc_id=6613 for LIMK1 gene. http://www.genenames.org/data/hgnc_data.php?hgnc_id=6614 for LIMK2 gene (Accessed August 1, 2011).
2. Manetti, F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med. Res. Rev. DOI:10.1002/med.20230.
3. Krcmery, J.; Camarata, T.; Kulisz, A.; Simon, H.-G. Nucleocytoplasmic functions of the PDZ-LIM protein family: new insights into organ development. BioEssays 2010, 32,100-108.
4. Kobayashi, N.; Niwa, M.; Hao, Y.; Yoshida, T. Nucleolar localization signals of LIM kinase 2 function as a cell-penetrating peptide. Protein Pept. Lett. 2010, 17, 1480-1488.
5. Sumi, T.; Hashigasako, A.; Matsumoti, K.; Nakamura, T. Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition. Exp. Cell Res. 2006, 312, 1021-1030.
6. Horita, Y.; Ohashi, K.; Mukai, M.; Inoue, M.; Mizuno, K. Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of slingshot or LIM kinase. J. Biol. Chem. 2008, 283, 6013-6021.
7. Nishita, M.; Tomizawa, C.; Yamamoto, M.; Horita, Y.; Ohashi, K.; Mizuno, K. Spatial and temporal regulation of cofilin activity by LIM kinase and Slingshot is critical for directional cell migration. J. Cell Biol. 2005, 171, 349-359.
8. Ahmed, T.; Shea, K.; Masters, J. R. W.; Jones, G. E.; Wells, C. M. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell. Signal. 2008, 20, 1320-1328.
9. Fu, Y.-M.; Yu, Z.-X.; Lin, H.; Fu, X.; Meadows, G. G. Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells. J. Cell. Physiol. 2008, 217, 184-193.
10. Gray, V.; Karmiloff-Smith, A.; Funnell, E.; Tassabehji, M. Indepth analysis of spatial cognition in Williams syndrome: A critical assessment of the role of the LIMK1 gene. Neuropsychologia 2006, 44, 679-685.
11. Heredia, L.; Helguera, P.; de Olmos, S.; Kedikian, G.; Sola Vigo, F.; LaFerla, F.; Staufenbiel, M.; de Olmos, J.; Busciglio, J.; Caceres, A.; Lorenzo, A. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid f-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J. Neurosci. 2006, 26, 6533-6542.
12. Bernard, O. Lim kinases, regulators of actin dynamics. Int. J. Biochem. Cell Biol. 2007, 39, 1071-1076.
13. Scott, R. W.; Olson, M. F. LIM kinases: function, regulation and association with human disease. J. Mol. Med. 2007, 85, 555-568.
14. Kip2 controls LIMkinase 1 activity and regulates actin cytoskeleton dynamics. Oncogene 2009, 28, 4175-4188.
15. Mishima, T.; Naotsuka, M.; Horita, Y.; Sato, M.; Ohashi, K.; Mizuno, K. LIM-kinase is critical for the mesenchymal-toamoeboid cell morphological transitino in 3D matrices. Biochem. Biophys. Res. Commun. 2010, 392, 577-581.
16. Song, X.; Chen, X.; Yamaguchi, H.; Mouneimne, G.; Condeelis, J. S.; Eddy, R. J. Initiation of cofilin activity in response to EGF is uncoupled from cofilin phosphorylation and dephosphorylation in carcinoma cells. J. Cell Sci. 2006, 119, 2871-2881.
17. Jovceva, E.; Larsen, M. R.; Waterfield, M. D.; Baum, B.; Timms, J. F. Dynamic cofilin phosphorylation in the control of lamellipodial actin homeostasis. J. Cell Sci. 2007, 120, 1888-1897.
18. Scott, R. W.; Hooper, S.; Crighton, D.; Li, A.; König, I.; Munro, J.; Trivier, E.; Wickman, G.; Morin, P.; Croft, D. R.; Dawson, J.; Machesky, L.; Anderson, K. I.; Sahai, E. A.; Olson, M. F. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J. Cell Biol. 2010, 191, 169-185.
19. Borensztajn, K.; Peppelenbosch, M. P.; Spek, C. A. Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thrombosis Res. 2010, 125, e323-e328.
20. Bagheri-Yarmand, R.; Mazumdar, A.; Sahin, A. A.; Kumar, R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int. J. Cancer 2006, 118, 2703-2710.
21. Klemke, M.; Kramer, E.; Konstandin, M. H.; Wabnitz, G. H.; Samstag, Y. An MEK-cofilin signalling module controls migration of human T cells in 3D but not 2D environments. EMBO J. 2010, 29, 2915-2929.
22. Amano, T.; Tanabe, K.; Eto, T.; Narumiya, S.; Mizuno, K. LIMkinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. Biochem. J. 2001, 354, 149-159.
23. Tomiyoshi, G.; Horita, Y.; Nishita, M.; Ohashi, K., Mizuno, K. Caspase-mediated cleavage and activation of LIM-kinase 1 and its role in apoptotic membrane blebbing. Genes Cells 2004, 9, 591-600.
24. Shea, K. F.; Wells, C. M.; Garner, A. P.; Jones, G. E. ROCK1 and LIMK2 interact in spread but not in blebbing cancer cells. PloS ONE 2008, 3, e3398.
25. Mizuno, K.; Okano, I.; Ohashi, K.; Nunoue, K.; Kuma, K.; Miyata, T.; Nakamura, T. Identification of a human cDNA encoding a novel protein kinase with two repeats of the lim/double zinc finger motif. Oncogene 1994, 9, 1605-1612.
26. Okano, I.; Hiraoka, J.; Otera, H.; Nunoue, K.; Ohashi, K.; Iwashita, S.; Hirai, M.; Mizuno, K. Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal lim motifs. J. Biol. Chem. 1995, 270, 31321-31330.
27. Yoshioka, K.; Foletta, V.; Bernard, O.; Ito, K. A role for LIM kinase in cancer invasion. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7247-7252.
28. Sidani, M.; Wessels, D.; Mouneimne, G.; Ghosh, M.; Goswami, S.; Sarmiento, C.; Wang, W.; Kuhl, S.; El-Sibai, M.; Backer, J. M.; Eddy, R.; Soll, D.; Condeelis, J. Cofilin determines the migration behavior and turning frequency of metastatic cancer cells. J. Chem. Biol. 2007, 179, 777-791.
29. Wang, W.; Mouneimne, G.; Sidani, M.; Wyckoff, J.; Chen, X.; Makris, A.; Goswami, S.; Bresnick, A. R.; Condeelis, J. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J. Cell Biol. 2006, 173, 395-404.
30. Mouneimne, G.; DesMarais, V.; Sidani, M.; Scemes, E.; Wang, W.; Song, X.; Eddy, R.; Condeelis, J. Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis. Curr. Biol. 2006, 16, 2193-2205.
31. Nishimura, Y.; Yoshioka, K.; Bernard, O.; Bereczky, B.; Itoh, K. A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem. Cell Biol. 2006, 126, 627-638.
32. Nishimura, Y.; Yoshioka, K.; Itoh, K. LIM kinase 1/cofilin signaling pathway plays a pivotal role in regulating EGF receptor endocytosis in invasive human breast cancer cells. In: Endocytosis Structural Components, Functions and Pathways; Dowler, B. C., Ed.; Nova Publishers: New York, 2010; pp. 141-159.
33. Davila, M.; Jhala, D.; Ghosh, D.; Grizzle, W. E.; Chakrabarti, R. Expression of LIMK kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer. Mol. Cancer 2007, 6, 40.
34. Misra, U. K.; Deedwania, R.; Pizzo, S. V. Binding of activated i2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J. Biol. Chem. 2005, 280, 26278-26286.
35. Davila, M.; Frost, A. R.; Grizzle, W. E.; Chakrabarti, R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J. Biol. Chem. 2003, 278, 36868-36875.
36. Suyama, E.; Wadhwa, R.; Kawasaki, H.; Yaguchi, T.; Kaul, S. C.; Nakajima, M.; Taira, K. LIM kinase-2 targeting as a possible antimetastasis therapy. J. Gene Med. 2004, 6, 357-363.
37. Vlecken, D. H.; Bagowski, C. P. LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells. Zebrafish 2009, 6, 433-439.
38. Zhang, H.; Li, Z.; Viklund, E. K.; Stromblad, S. p21-Activated kinase 4 interacts with integrin kvv5 and regulates 5vv5-mediated cell migration. J. Cell Biol. 2002, 158, 12877-1297.
39. Li, X.; Ke, Q.; Li, Y.; Liu, F.; Zhu, G.; Li, F. DGCR6L, a novel PAK4 interaction protein, regulates PAK4-mediated migration of human gastric cancer cell via LIMK1. Int. J. Biochem. Cell Biol. 2010, 42, 70-79.
40. Pfuhl, T.; Dürr, M.; Spurk, A.; Schwalbert, B.; Nord, R.; Mysliwietz, J.; Kremmer, E.; Grässer, F. A. Biochemical characterisation of the proteins encoded by the DiGeorge critical region 6 (DGCR6) genes. Hum. Genet. 2005, 117, 70-80.
41. Euer, N.; Schwirzke, M.; Evtimova, V.; Burtscher, H.; Jarsch, M.; Tarin, D.; Weidle, U. H. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus nonmetastatic cell lines. Anticancer Res. 2002, 22, 733-740.
42. Ding, Y.; Milosavljevic, T.; Alahari, S. K. Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol. Cell Biol. 2008, 28, 3742-3756.
43. Liu, Y.; Wang, J.; Wu, M.; Wan, W.; Sun, R.; Yang, D.; Sun, X.; Ma, D.; Ying, G.; Zhang, N. Down-regulaton of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol. Cancer Res. 2009, 7, 944-954.
44. Chrenek, M. A.; Wong, P.; Weaver, V. m. Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res. 2001, 3, 224-229.
45. Gorovoy, M.; Han, J.; Pan, H.; Welch, I.; Neamu, R.; Jia, Z.; Predescu, D.; Vogel, S.; Minshall, R. D.; Ye, R. D.; Malik, A. B.; Voyno-Yasenetskaya, T. LIM kinase 1 promotes endothelial barrier disruption and neutrophil infiltration in mouse lungs. Circ. Res. 2009, 105, 549-556.
46. Miyazaki, T.; Honda, K.; Ohata, H. m-Calpain antagonizes RhoA overactivation and endothelial barrier dysfunction under disturbed shear conditions. Cardiovasc. Res. 2010, 85, 530-541.
47. Mancini, M.; Corradi, V.; Petta, S.; Barbieri, E.; Manetti, F.; Botta, M.; Santucci, M. A. A new non-peptidic inhibitor of the 14-3-3 docking site induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J. Pharmacol. Exp. Ther. 2011, 336, 596-604.
48. Corradi, V.; Mancini, M.; Manetti, F.; Petta, S.; Santucci, M. A.; Botta, M. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg. Med. Chem. Lett. 2010, 20, 6133-6137.
49. Radi, M.; Crespan, E.; Falchi, F.; Bernardo, V.; Zanoli, S.; Manetti, F.; Schenone, S.; Maga, G.; Botta, M. Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors. ChemMedChem 2010, 5, 1226-1231.
50. Santucci, M. A.; Corradi, V.; Mancini, M.; Manetti, F.; Radi, M.; Schenone, S.; Botta, M. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. ChemMedChem 2009, 4, 118-126.
51. Manetti, F.; Brullo, C.; Magnani, M.; Mosci, F.; Chelli, B.; Crespan, E.; Schenone, S.; Naldini, A.; Bruno, O.; Trincavelli, M. L.; Maga, G.; Carraro, F.; Martini, C.; Bondavalli, F.; Botta, M. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J. Med. Chem. 2008, 51, 1252-1259.
52. Kuzelova, K.; Hrkal, Z. Rho-signaling pathways in chronic myelogenous leukemia. Cardiovasc. Hematol. Disord. Drug Targets 2008, 8, 261-267.
53. Gao, Y.; Dickerson, J. B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7618-7623.
54. Olson, M. F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 2008, 20, 242-248.
55. Morin, P.; Wickman, G.; Munro, J.; Inman, G. J.; Olson, M. F. Differing contributions of LIMK and ROCK to TGFD-induced transcription, motility and invasion. Eur. J. Cell Biol. 2011, 90, 13-25.
56. Hahmann, C.; Schroeter, T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 2010, 67, 171-177.
57. Po'uha, S. T.; Shum, M. S. Y.; Goebel, A.; Bernard, O.; Kavallaris, M. LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubuledestabilizing drugs. Oncogene 2010, 29, 597-607.
58. Yuen, G. S.; McEwen, B. S.; Akama, K. T. LIM kinase mediates estrogen action on the actin depolymerization factor cofilin. Brain Res. 2011, 1379, 44-52.
59. Gaestel, M. MAPKAP kinases-MKs-two's company, three's a crowd. Nat. Rev. Mol. Cell Biol. 2006, 7, 120-130.
60. Cote, M. C.; Lavoie, J. R.; Houle, F.; Poirier, A.; Rousseau, S.; Huot, J. Regulation of vascular endothelial growth factor-induced endothelial cell migration by LIM kinase 1-mediated phosphorylation of annexin 1. J. Biol. Chem. 2010, 285, 8013-8021.
61. Hoogwater, F. J.; Nijkamp, M. W.; Smakman, N.; Steller, E. J.; Emmink, B. L.; Westendorp, B. F.; Raats, D. A.; Sprick, M. R.; Schaefer, U.; van Houdt, W. J.; De Bruijn, M. T., Schackmann, R. C.; Derksen, P. W.; Medema, J. P.; Walczak, H.; Borel Rinkes, I. H.; Kranenburg, O. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138, 2357-2367.
62. Mikula, M.; Schreiber, M.; Husak, Z.; Kucerova, L.; Rüth, J.; Wieser, R.; Zatloukal, K.; Beug, H.; Wagner, E. F.; Baccarini, M. Embryonic lethality and fetal liver apoptosis in mice lacking the craf-1 gene. EMBO J. 2001, 20, 1952-1962.
63. Chhavi; Saxena, M.; Singh, S.; Negi, M.; Srivastava, A. K.; Trivedi, R.; Singh, U.; Pant, M. C.; Bhatt, M. Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. J. Cancer Res. Ther. 2010, 6, 167-171.
64. Arvanitis, D. A.; Spandidos, D. A. Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study. Oncol. Rep. 2008, 20, 751-760.
65. Córdova-Alarcón, E.; Centeno, F.; Reyes-Esparza, J.; García-Carrancá, A.; Garrido, E. Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch. Med. Res. 2005, 36, 311-316.
66. Borensztajn, K.; Bijlsma, M. F.; Reitsma, P. H.; Peppelenbosch, M. P.; Spek, C. A. Coagulation Factor Xa inhibits cancer cell migration via protease-activated receptor-1 activation. Thrombosis Res. 2009, 124, 219-225.
67. Lazova, R.; Gould Rothberg, B. E.; Rimm, D.; Scott, G. The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am. J. Dermatopathol. 2009, 31, 177-181.
68. Scott, G. A.; McClelland, L. A.; Fricke, A. F.; Fender, A. Plexin C1, a receptor for semaphorin 7A, inactivates cofilin and is a potential tumor suppressor for melanoma progression. J. Invest. Dermatol. 2009, 129, 954-963.
69. Scott, G. Tumor suppression through Plexin C1. WO 2009/155310 A1, December 23, 2009.
70. Van Goietsenoven, G.; Hutton, J.; Becker, J. P.; Lallemand, B.; Robert, F.; Lefranc, F.; Pirker, C.; Vandenbussche, G.; Van Antwerpen, P.; Evidente, A.; Berger, W.; Prevost, M.; Pelletier, J.; Kiss, R.; Kinzy, T. G.; Kornienko, A.; Mathieu, V. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010, 24, 4575-4584.
71. Lefranc, F.; Sauvage, S.; Van Goietsenoven, G.; Megalizzi, V.; Lamoral-Theis, D.; Debeir, O.; Spiegl-Kreinecker, S.; Berger, W.; Mathieu, V.; Decaestecker, C.; Kiss, R. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol. Cancer Ther. 2009, 8, 1739-1750.
72. Olivier, M.; Eeles, R.; Hollstein, M.; Khan, M. A.; Harris, C. C.; Hainaut, P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19, 607-414.
73. Olsson, A.; Manzl, C.; Strasser, A.; Villunger, A. How important are post-translational modifications in p53 for selectivity in targetgene transcription and tumour suppression? Cell Death Differ. 2007, 14, 1561-1575.
74. Murray-Zmijewski, F.; Slee, E. A.; Lu, X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol. 2008, 9,702-712.
75. Gadea, G.; de Toledo, M.; Anguille, C.; Roux, P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 2007, 178, 23-30.
76. Guo, F.; Gao, Y.; Wang, L.; Zheng, Y. p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J. Biol. Chem. 2003, 278, 14414-14419.
77. Hsu, F.-F.; Lin, T.Y.; Chen, J.-Y.; Shieh, S.-Y. p53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control. Oncogene 2010, 29, 2864-2876.
78. Machado, R. D.; Pauciulo, M. W.; Thomson, J. R.; Lane, K. B.; Morgan, N. V.; Wheeler, L.; Philips, J. A., III; Newman, J.; Williams, D.; Galie, N.; Manes, A.; McNeil, K.;, Yacoub, M.; Mikhail, G.; Rogers, P.; Corris, P.; Humbert, M.; Donnai, D.; Martensson, G.; Tranebjaerg, L.; Loyd, J. E.; Trembath, R. C.; Nichols, W. C. BMPRII haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 2001, 68, 92-102.
79. West, J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv. Exp. Med. Biol. 2010, 661, 265-78.
80. Lim, M. K.; Kawamura, T.; Ohsawa, Y.; Ohtsubo, M.; Asakawa, S.; Takayanagi, A.; Shimizu, N. Parkin interacts with LIM kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. Exp. Cell Res. 2007, 313, 2858-2874.
81. Akagawa, H.; Tajima, A.; Sakamoto, Y.; Krischek, B.; Yoneyama, T.; Kasuya, H.; Onda, H.; Hori, T.; Kubota, M.; Machida, T.; Saeki, N.; Hata, A.; Hashiguchi, K.; Kimura, E.; Kim, C. J.; Yang, T. K.; Lee, J. Y.; Kimm, K.; Inoue, I. A haplotype spanning two genes, ELN and LIMK1, decreases their transcripts and confers susceptibility to intracranial aneurysms. Hum. Mol. Genet. 2006, 15, 1722-1734.
82. Low, S. K.; Zembutsu, H.; Takahashi, A.; Kamatani, N.; Cha, P. C.; Hosono, N.; Kubo, M.; Matsuda, K.; Nakamura, Y. Impact of LIMK1, MMP2 and TNF-α variations for intracranial aneurysm in Japanese population. J. Hum. Genet. 2011, 56, 211-216.
83. Kuzmin, A.; Jarvi, K.; Lo, K.; Spencer, L.; Chow, G. Y.; Macleod, G.; Wang, Q.; Varmuza, S. Identification of potentially damaging amino acid substitutions leading to human male infertility. Biol. Reprod. 2009, 81, 319-326.
84. Honma, M.; Aznar Benitah, S.; Watt, F. M. Role of LIM kinases in normal and psoriatic human epidermis. Mol. Biol. Cell 2006, 17, 1888-1896.
85. Mustafa, S.; Vasudevan, H.; Yuen, V. G.; McNeill, J. H. Renal expression of arachidonic acid metabolizing enzymes and RhoA/Rho kinases in fructose insulin resistant hypertensive rats. Mol. Cell Biochem. 2010, 333, 203-209.
86. Harrison, B. A.; Whitlock, N. A.; Voronkov, M. V.; Almstead, Z. Y.; Gu, K.; Mabon, R.; Gardyan, M.; Hamman, B. D.; Allen, J.; Gopinathan, S.; McKnight, B.; Crist, M.; Zhang, Y.; Liu, Y.; Courtney, L. F.; Key, B.; Zhou, J.; Patel, N.; Yates, P. W.; Liu, Q.; Wilson, A. G. E.; Kimball, S. D.; Crosson, C. E.; Rice, D. S.; Rawlins, D. B. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J. Med. Chem. 2009, 52, 6515-6518.
87. Wrobelski, S. T.; Lin, S.; Leftheris, K.; He, L.; Seitz, S. P.; Lin, T.-A.; Vaccaro, W. Phenyl-substituted pyrimidine compounds useful as kinase inhibitors. WO 2006/084017 A2, August 10, 2006.
88. Sleebs, B. E.; Street, I. P.; Bu, X.; Baell, J. B. De novo synthesis of a potent LIMK1 inhibitor. Synthesis 2010, 7, 1091-1096.
89. Ross-Macdonald, P.; de Silva, H.; Guo, Q.; Xiao, H.; Hung, C.-Y.; Penhallow, B.; Markwalder, J.; He, L.; Attar, R. M.; Lin, T.; Seitz, S.; Tilford, C.; Wardwell-Swanson, J.; Jackson, D. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol. Cancer Ther. 2008, 7, 3490-3498.
90. Harrison, B. A.; Kimball, S. D.; Mabon, R.; Rawlins, D. B.; Rice, D. S.; Voronkov, M. V.; Zhang, Y. Kinase inhibitors, compositions comprising them, and methods of their use. WO 2009/021169 A2, February 12, 2009.
91. Burgoon, H. A.; Goodwin, N. C.; Harrison, B. A.; Healy, J. P.; Liu, Y.; Mabon, R.; Marinelli, B.; Rawlins, D. B.; Rice, D. S.; Whitlock, N. A. LIMK inhibitors, compositions comprising them, and methods of their use. WO 2009/131940 A1, October 29, 2009.
92. Sleebs, E. B.; Nikolakopoulos, G.; Street, I. P.; Falk, H.; Baell, J. B. Identification of 5,6-substitued 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 5992-5994.
93. Feng, Y.; Lograsso, P.; Schroeter, T.; Yin, Y. Preparation of pyrazolylphenyl urea and carbamate compounds and analogs as kinase inhibitors. WO 2010/036316 A1, April 1, 2010.
94. Lafanechere, L.; Vassal, E.; Barette, C.; Nguyen, C.; Rivale, C.; Prudent, R. Pyridocarbazole-type compounds, their preparation and use for preventing and/or treating of cancer, Alzheimer's disease, schizophrenia, parasitoses and glaucomas. WO 2010/095042, August 26, 2010.
95. Roy, P.; Kalra, N.; Nigam, N.; George, J.; Ray, R. S.; Hans, R. K.; Prasad, S.; Shukla, Y. Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-tB pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun. 2009, 384, 215-220.
96. Panitch, A.; Seal, B. Kinases inhibitors and uses thereof. WO 2009/021137 A2, February 12, 2009.
97. Panitch, A.; Seal, B. Cell-permeant peptide-based inhibitor of kinases. WO 2010/068692, June 17, 2010.
98. Bitter, H. M. L.; Goldstein, D. M.; Gonzaludo, N.; Kirchner, S.; Kolaja, K. L.; Olaharski, A. J. Predition of genotoxicity. WO 2010/069612, June 24, 2010.
99. The UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 2011, 39: D214-D219.
100. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; Gibson, T. J.; Higgins, D. G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23, 2947-2948.
101. Smith, T. F.; Waterman, M. S. Identification of common molecular subsequences. J. Mol. Biol. 1981, 147, 195-197.
102. SSEARCH program, version 3.4t24. Protein Information Resource. http://pir.georgetown.edu/pirwww/search/pairwise.shtml (Accessed August 1, 2011).